相关实验视频
Updated: May 24, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
塔苏格拉提尼布糖酸盐:首次获得批准
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
塔苏格拉提尼布糖酸盐是一种新的口服药物,在日本批准用于晚期胆道癌症. 它针对患有FGFR2融合的患者的纤维细胞生长因子受体 (FGFRs).
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 塔苏格拉提尼酸盐是一种口服活跃的小分子抑制剂,向纤维细胞生长因子受体 (FGFRs) 1,2和3.
- 它正在开发用于各种固体瘤,包括胆管癌和乳腺癌.
研究的目的:
- 为了总结tasurgratinib succinate的发展里程碑.
- 为了突出其首次批准用于胆道癌症.
主要方法:
- 在日本和中国进行了一项开放式,单臂,多中心的II期研究.
- 该研究评估了FGFR2融合阳性不可切除的胆道癌症患者的tasurgratinib苏酸.
主要成果:
- 塔苏格拉提尼布酸盐于2024年9月24日在日本获得了首次批准.
- 该批准是用于治疗FGFR2融合阳性不可切除的胆道癌症,该癌症在化疗后进展.
结论:
- 塔苏格拉提尼布糖代表了胆道癌症治疗的重大进展.
- 此次批准标志着该药物用于固体瘤的开发的一个关键里程碑.
更多相关视频
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists